Thioridazine

Indications

Its primary use in medicine is for the treatment of schizophrenia. It was also tried with some success as a treatment for various psychiatric symptoms seen in people with dementia, but chronic use of thioridazine and other anti-psychotics in people with dementia is not recommended.

Side effects

Thioridazine prolongs the QTc interval in a dose-dependent manner. It produces significantly less extrapyramidal side effects than most first-generation antipsychotics, likely due to its potent anticholinergic effect. Its use, along with the use of other typical antipsychotics, has been associated with degenerative retinopathies (specifically retinitis pigmentosa). It has a higher propensity for causing anticholinergic side effects coupled with a lower propensity for causing extrapyramidal side effects and sedation than chlorpromazine, but also has a higher incidence of hypotension and cardiotoxicity. It is also known to possess a relatively high liability for causing orthostatic hypotension compared to other antipsychotics. Similarly to other first-generation antipsychotics it has a relatively high liability for causing prolactin elevation. It is moderate risk for causing weight gain. As with all antipsychotics thioridazine has been linked to cases of tardive dyskinesia (an often permanent neurological disorder characterised by slow, repetitive, purposeless and involuntary movements, most often of the facial muscles, that is usually brought on by years of continued treatment with antipsychotics, especially the first-generation (or typical) antipsychotics such as thioridazine) and neuroleptic malignant syndrome (a potentially fatal complication of antipsychotic treatment). Blood dyscrasias such as agranulocytosis, leukopenia and neutropenia are possible with thioridazine treatment. Thioridazine is also associated with abnormal retinal pigmentation after many years of use. Thioridazine has been correlated to rare instances of clinically apparent acute cholestatic liver injury.

Pharmacology

Thioridazine has the following binding profile:

Note: The Binding affinities given are towards cloned human receptors unless otherwise specified

Acronyms used

HB – Human brain receptor

RC – Cloned rat receptor

ND – No data

Metabolism

Thioridazine is a racemic compound with two enantiomers, both of which are metabolized, according to Eap et al., by CYP2D6 into (S)- and (R)-thioridazine-2-sulfoxide, better known as mesoridazine, and into (S)- and (R)-thioridazine-5-sulfoxide. Mesoridazine is in turn metabolized into sulforidazine. Thioridazine is an inhibitor of CYP1A2 and CYP3A4.

History

Thioridazine was first synthesized in 1958 by Swiss pharmaceutical company Sandoz. It quickly entered widespread clinical use, as there were few alternatives for treating schizophrenia. In 2005, thioridazine was voluntarily discontinued by its manufacturer, Novartis, worldwide because it caused severe cardiac arrhythmias. However, generics remain on the market in some countries. Generic forms of thioridazine however remain on the market in a few countries, usually with restrictions. For example, in the US it is restricted to patients who have taken at least 2 other antipsychotics that either failed or caused serious side effects.

Antimicrobial activity

Thioridazine is known to kill extensively drug-resistant tuberculosis and to make methicillin-resistant Staphylococcus aureus sensitive to β-lactam antibiotics. A possible mechanism of action for the drug's antibiotic activity is via the inhibition of bacterial secretion pumps. The β-lactam antibiotic resistance is due to the secretion β-lactamase, a protein that destroys antibiotics. If the bacteria cannot secrete the β-lactamase, then the antibiotic will be effective. Phenothiazines more broadly have also been used in combination with other drugs to treat infections caused by pathogenic free living amoeba (PFLA).

Synthesis

Note: Same sidechain used for mesoridazine and sulforidazine.

The alkylation of 2-Picoline [109-06-8] (1) with formaldehyde gives 2-Pyridineethanol [103-74-2] (2). Forming the quat salt with methyl iodide [74-88-4] leads to 2-(2-hydroxyethyl)-1-methyl-pyridinium iodide [56622-15-2] (3). Catalytic hydrogenation in the presence of hydrochloric acid leads to 2-(2-Chloroethyl)-1-Methylpiperidine [50846-01-0] (4). Alkylation of 2-Methylthiophenothiazine [7643-08-5] (5) in the presence of sodium hydride base completed the synthesis of Thioridazine (6).

References

References

1. (2023-03-31). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial". [[Diário Oficial da União]].
2. (August 1984). "Blood levels of haloperidol and thioridazine during maintenance neuroleptic treatment of schizophrenic outpatients". Journal of Clinical Psychopharmacology.
3. (March 2012). "SHARED CARE PROTOCOL Thioridazine". NHS Lothian Joint Formulary.
4. (2011). "Goodman & Gilman's The Pharmacological Basis of Therapeutics". McGraw-Hill.
5. (2001). "Thioridazine for dementia". The Cochrane Database of Systematic Reviews.
6. (March 2013). "Withdrawal versus continuation of chronic antipsychotic drugs for behavioural and psychological symptoms in older people with dementia". The Cochrane Database of Systematic Reviews.
7. (September 2010). "THIORIDAZINE HYDROCHLORIDE tablet, film coated [Mutual Pharmaceutical]". Mutual Pharmaceutical.
8. (July 2007). "Thioridazine for schizophrenia". The Cochrane Database of Systematic Reviews.
9. (November 1994). "The Australian multicentre double-blind comparative study of remoxipride and thioridazine in schizophrenia". Acta Psychiatrica Scandinavica.
10. (July 2002). "Pathogenesis of degenerative retinopathies induced by thioridazine and other antipsychotics: a dopamine hypothesis". Documenta Ophthalmologica. Advances in Ophthalmology.
11. (18 August 2010). "Martindale: The Complete Drug Reference". The Pharmaceutical Press.
12. "Selected adverse effects of antipsychotic medications for schizophrenia". Wolters Kluwer Health.
13. (December 1963). "Retinal Pigmentation in a Patient Receiving Thioridazine". Archives of Ophthalmology.
14. (2012). "LiverTox: Clinical and Research Information on Drug-Induced Liver Injury". National Institute of Diabetes and Digestive and Kidney Diseases.
15. (12 January 2011). "PDSP K_i Database". University of North Carolina at Chapel Hill and the United States National Institute of Mental Health.
16. "Mesoridazine". National Center for Biotechnology Information.
17. (March 1996). "Plasma levels of the enantiomers of thioridazine, thioridazine 2-sulfoxide, thioridazine 2-sulfone, and thioridazine 5-sulfoxide in poor and extensive metabolizers of dextromethorphan and mephenytoin". Clinical Pharmacology and Therapeutics.
18. "Sulforidazine". National Center for Biotechnology Information.
19. (2001). "Effects of phenothiazine neuroleptics on the rate of caffeine demethylation and hydroxylation in the rat liver". Polish Journal of Pharmacology.
20. (1989). "Analytical profiles of drug substances". Academic Press.
21. (November 2012). "Outcome of patients after market withdrawal of thioridazine: a retrospective analysis in a nationwide cohort". Pharmacoepidemiology and Drug Safety.
22. (2005). "WHO Pharmaceuticals Newsletter 2005, No. 04: REGULATORY MATTERS: Thioridazine - Sale discontinued in Canada". World Health Organization.
23. (June 2007). "Withdrawal of thioridazine". Australian Prescriber.
24. "Thioridazine: MedlinePlus Drug Information".
25. (June 2010). "Thioridazine cures extensively drug-resistant tuberculosis (XDR-TB) and the need for global trials is now!". International Journal of Antimicrobial Agents.
26. (May 2012). "Why thioridazine in combination with antibiotics cures extensively drug-resistant Mycobacterium tuberculosis infections". International Journal of Antimicrobial Agents.
27. (November 2007). "Thioridazine: resurrection as an antimicrobial agent?". British Journal of Clinical Pharmacology.
28. (May 2013). "Thioridazine induces major changes in global gene expression and cell wall composition in methicillin-resistant Staphylococcus aureus USA300". PLOS ONE.
29. (November 2003). "Successful treatment of Balamuthia amoebic encephalitis: presentation of 2 cases". Clinical Infectious Diseases.
30. (1958). "Synthesen auf dem Phenothiazin-Gebiet. 2. Mitteilung. N-substituierte Mercaptophenothiazin-Derivate". Helvetica Chimica Acta.
31. "Phenothiazine derivatives substituted by a monovalent sulfur function in 3-position".
32. (August 1946). "The synthesis of some substituted 8-aminoquinolines". Journal of the American Chemical Society.
33. (2020). "Synthesis of the enantiomers of thioridazine.". SynOpen.